Skip to main content
Premium Trial:

Request an Annual Quote

Bottoms Up!

Australian Nobel Laureate Barry Marshall — lauded for his discovery of the stomach-dwelling bacterium Helicobacter pylori's role in gastritis and peptic-ulcer disease — plans to put the bug that made him famous to use in science's battle against the flu, Bloomberg reports. By mid-2013, Marshall said he expects the biotech firm he founded, Ondek Ltd., to report results for a clinical trial of a drinkable flu vaccine. Researchers aim to use the vaccine "to harness the ability of the bacterium … to colonize the stomach," such that its "harmful genes will be removed and those from influenza and other viruses will be inserted to stimulate an immune response," according to Bloomberg. In a preliminary study, Marshall and his team showed that "some [vaccine] strains were capable of safely colonizing the gut, proving the concept is feasible," Bloomberg adds.

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.